Transplantation of adult neural progenitor cells transfected with Vascular Endothelial Growth Factor rescues grafted cells in the rat brain by Maurer, Martin H. et al.
Int. J. Biol. Sci. 2008, 4 
 
1
International Journal of Biological Sciences 
ISSN 1449-2288 www.biolsci.org 2008 4(1):1-7 
©Ivyspring International Publisher. All rights reserved 
Short Research Communication 
Transplantation of adult neural progenitor cells transfected with Vascular 
Endothelial Growth Factor rescues grafted cells in the rat brain 
Martin H. Maurer1,2, Christine Thomas1, Heinrich F. Bürgers1, Wolfgang Kuschinsky1 
1.  Department of Physiology and Pathophysiology, University of Heidelberg, Heidelberg, Germany. 
2.  Present address: SYGNIS Bioscience, Im Neuenheimer Feld 515, 69120 Heidelberg, Germany.  
Correspondence to: Dr. Martin H. Maurer, Dept. of Physiology and Pathophysiology, University of Heidelberg, Im Neuenheimer Feld 326, 
69120 Heidelberg, Germany. Phone: +49-6221-54-4032; Fax: +49-6221-54-4561; Email: maurer@physiologie.uni-heidelberg.de 
Received: 2007.10.19; Accepted: 2007.11.30; Published: 2007.12.03 
Growth factors are currently evaluated as therapeutics in stroke and neurodegeneration. Besides direct 
neurotrophic effects, they promote proliferation, survival, and differentiation of both transplanted and 
endogenous neural precursor cells (NPCs). In the current study, we investigated whether NPCs expressing 
Vascular Endothelial Growth Factor VEGF-A165 are a useful vehicle for growth factor delivery after 
transplantation into the caudate putamen of the rat brain. We found an increased survival of adenovirally 
transfected NPCs after 11 days, but not after 24 hours or 4 days. Additional brain immunohistochemistry 
revealed increased expression of the endothelial cell marker PECAM-1 (CD31) after 24 hours, 4 day, and 11 days 
after transplantation. In conclusion, we show that the graft itself is a useful vehicle for growth factor delivery, 
promoting the survival of NPCs. Moreover, transplantation of VEGF-expressing NPCs supports angiogenesis in 
the brain, which may contribute to potential brain repair.  
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1.  Introduction 
Hematopoietic and angiogenic growth factors are 
currently re-considered as therapeutical agents in a 
number of neurological diseases, mainly 
neurodegenerative disorders like Parkinson's Disease, 
amyotrophic lateral sclerosis (ALS), or cerebrovascular 
events such as stroke. The major advantage of these 
growth factors is their well-described pharmacological 
behavior and their clinical use over several years 
which ensure drug safety. Although their molecular 
mechanism of drug action in the brain is not clearly 
identified, they all relate to neuroplasticity and stem 
cell growth and differentiation. Among the growth 
factors with neuroregenerative potential are 
erythropoietin (EPO) [1], granulocyte-colony 
stimulating factor (G-CSF) [2], and the vascular 
endothelial growth factor (VEGF) [3]. 
Originally, VEGF was described as angiogenesis 
factor, since one of its biological roles is promoting 
angiogenesis by sprouting and branching of 
pre-existing blood vessels. Additionally, VEGF 
prevents neurodegeneration [4, 5] and promotes 
neurogenesis [3] in vitro and in vivo. Neuroprotection 
in animal models of Amyotrophic Lateral Sclerosis 
(ALS) [6-8] have nurtured the hope of a therapeutical 
use of VEGF.  
The VEGF protein family is constituted of at least 
7 members (VEGF-A to -E, and PlGF-1 and -2), of 
which the VEGF-A isoform is represented by several 
splice variants [9, 10]. The VEGF isoforms bind to 
specific receptors, including VEGF-R1 (flt-1), VEGF-R2 
(KDR, flk-2), VEGF-R3 (flt-4), Neuropilin-1, 
Neuropilin-2, and heparan-sulfate proteoglycans [9, 
10]. The angiogenic signals are mediated by the 
tyrosine kinases linked to VEGF-R1 and VEGF-R2 
[11-14], whereas only little is known about the 
neuroprotective and neuroregenerative signal 
transduction processes. 
In recent years, the transplantation of neural stem 
or progenitor cells -whether of embryonic or adult 
origin- has been discussed as an alternative to the 
a c t i v a t i o n  o f  e n d o g e n o u s  s t e m  c e l l s  r e s i d i n g  i n  t h e  
brain (for review, see [15]). In most paradigms, either 
the stem/progenitor cells or the growth factor are 
injected into the brain tissue. Therefore, we 
investigated in the present study whether the graft 
itself is a useful vehicle for the growth factor VEGF. 
Whereas a number of studies have shown the effects of 
VEGF in the diseased brain, we focused in the present 
study on transplantation into the intact, non-diseased 
brain to exclude cellular signaling by other means than 
VEGF, e. g. inflammation. 
2.  Material and Methods 
Cell culture 
NPCs were isolated from the subventricular zone 
of 4-6 weeks old male Wistar rats as described [3, 16]. 
Protocols are concordant with the policy on the use of 
animals, as endorsed by the National Institutes of 
Health, and fulfill the requirements of German law. 
Briefly, brains were washed in 50 mL ice-cold 
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supplemented with 4.5 g/L glucose (DPBS/Glc). 
Subventricular zones from 6 animals were dissected, 
washed in 10 mL DPBS/Glc and centrifuged for 5 min 
at 1600 x g at 4 °C. After removal of the supernatant, 
the tissue was homogenized with scissors and scalpels, 
resuspended in 20 mL DPBS/Glc, and centrifuged for 
5 min at 1600 x g at 4 °C. The pellet was resuspended in 
10 mL of 0.01 % (w/v) papain, 0.1 % (w/v) dispase II 
(neutral protease), 0.01 % (w/v) DNase I, 12.4 mM 
MgSO4 in Hank’s Balanced Salt Solution (HBSS), 
triturated well by a plastic pipette tip, and incubated at 
room temperature for 40 min. In three washing steps, 
the homogenate was centrifuged for 5 min at 1600 x g a 
4 °C and the pellet was resuspended in 10 mL 
Dulbecco’s Modified Eagle’s Medium (DMEM)-Ham’s 
F12 medium supplemented with 100 units/mL 
penicillin, 100 units/mL streptomycin, and 2 mM 
L-glutamine. Cells were resuspended in 1 mL 
neurobasal-B27 medium and the cell number was 
counted. Cells were plated in 2 mL dishes at 200,000 
cells in B27-neurobasal medium supplemented with 
100 units/mL penicillin, 100 units/mL streptomycin, 
20 ng/mL EGF, 20 ng/mL FGF-2, and 2 µg/mL 
heparin. A total of 4/5 of the medium was replaced 
weekly, and cells were passaged every 2-2.5 weeks. 
The neural stem cells were maintained for 6-10 weeks 
in 5 % CO2 at 37 °C.   
Immunocytochemistry for marker proteins in 
neurospheres before transplantation 
The following primary antibodies directed 
against marker proteins for precursor cells have been 
used: for NPC markers, nestin (1:100; BD Pharmingen, 
Heidelberg, Germany), doublecortin (1:100; Chemicon, 
Temecula, CA, USA); for neuronal markers, tubulin 
ßIII, clone TuJ-1 (1:100; Abcam, Cambridge, UK) and 
neurofilament 70 kDa NF70 (1:200; Chemicon); for 
astrocytes, glial acidic fibrillary protein GFAP (1:500; 
BD Pharmingen); for oligodendrocytes, O4 (1:100; 
Neuromics, Edina, MN, USA); and endothelial 
cells/capillaries CD31 (1:100; BD Pharmingen).   
Neurospheres were grown adhesively on 
poly-L-lysin covered slides, fixed in 4% 
paraformaldehyde in PBST, pH 7.4 for 10 min and 
washed three times in PBST for 5 min each. Then the 
slides were blocked for 30 min in Seablock solution 
(Pierce, Rockford, IL, USA) and washed three times in 
PBST for 5 min each. The respective primary antibody 
was applied overnight at 4 °C in a humidified 
chamber. The next day, the slides were washed 3 times 
for 5 min in PBST. For double staining, the second 
primary antibody was applied. Then the sections were 
incubated with the respective FITC- or 
TRITC-conjugated secondary antibody (1:200, Jackson 
ImmunoResearch, West Grove, PA, USA) for 3 h at 
room temperature. After washing 3 times for 5 min 
each with PBST, nuclei were stained with 
4',6-diamidino-2-phenylindole (DAPI, 1:5,000, 
Molecular Probes, Eugene, OR, USA) for 5 min. Slides 
were embedded in fluoprotective mounting media [17] 
and stored at 4 °C in the dark until fluorescence 
microscopy.  
Labeling and adenoviral transfection of neural 
progenitor cells before transplantation 
For pulse labeling of the neural stem cells before 
transplantation, the thymidine analogue 
5‘-bromo-2-deoxy-uridine (BrdU; BrdU Labeling and 
Detection Kit I, Roche Diagnostics, Mannheim, 
Germany) was added to the cell culture medium daily 
in a final concentration 1 µmol/L for 48 h. This allowed 
tracking of the grafted cells after transplantation.  
Neural stem cells were transfected using the 
adenoviral vector AdPAC-VEGF as described 
previously [18]. Briefly, the vector containing the 
VEGF-A165 gene was added to a single cell suspension 
of neural stem cells at a final concentration of 1.2 * 108 
viral particles and incubated for 4 days. The VEGF 
concentration in the cell culture medium was 
determined using an ELISA kit according to the 
manufacturer's instructions (BioSource International, 
Camarillo, CA, USA). The transfection efficiency in the 
cell culture was determined by cell counting as 
described elsewhere in detail [16]. Briefly, after 
sampling of a small drop of cell culture media 
containing neurospheres and freezing on a slide under 
a cover slip for 20 min at 80 °C, the immunostaining 
protocol for BrdU followed according to the same 
methodology described below for tissue sections. 
Transplantation of neural progenitor cells 
For transplantation, we used a modified protocol 
published previously [19]. Cells were trypsinized at 37 
°C for 2 min and mechanically dissociated to a single 
cell suspension. The transplant consisted of 1,000,000 
cells (5 µL total volume) and was injected into the 
caudate putamen at AP +0.5 mm, L ±2.5 mm, DV -6.0 
mm using a stereotactic apparatus (David Kopf 
Instruments, Tujunga, CA, USA). Four animals each 
were attributed to the experimental and control 
groups. The rats were decapitated after 24 h, 4 d, and 
11 d, respectively. After removal of the skin and 
muscular tissue, the skull was opened by a circular 
incision. The brain was removed using a fine spatula 
and immersed in -80 °C cold isopentane. Due to its 
high coefficient of heat conductance, isopentane allows 
fast and complete freezing of large tissue samples. The 
tissue was stored at -80 °C until used. Frontal or 
sagittal cryosections, respectively, of 20 µm were cut. 
The relative position of the section in the brain was 
determined using the stereotactic atlas of Paxinos and 
Watson [20].  
Immunohistochemistry for BrdU after transplantation 
The sections were fixed in -20 °C methanol 
containing 1% (v/v) H2O2 for 20 min. Then the slides 
were washed once in bidestilled water for 5 min, and 
twice in PBST for 5 min each. For DNA denaturation, 
the sections were treated in 2 N HCl for 30 min at 37 °C 
in a prewarmed water bath. For neutralization, the 
slides were washed twice for 5 min each in 0.1 M 
sodium borate buffer, pH 8.5. Then the sections were 
washed in PBST twice for 5 min each. After blocking of Int. J. Biol. Sci. 2008, 4 
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unspecific epitopes with SeaBlock (Pierce, Rockford, 
IL, USA) for 30 min, the primary anti-BrdU antibody 
(1:50 in PBST; clone BU1/75 (ICR1), Accurate 
Chemical and Scientific Co., Westbury, NY, USA) was 
applied overnight at 4 °C. The next day, sections were 
washed 3 times in PBST for 5 min each, and the 
FITC-labelled secondary antibody (Dianova, 
Hamburg, Germany) was applied for 2 h at room 
temperature. After washing tree times in PBST, slides 
were embedded in fluoprotective mounting media [17] 
and stored at 4 °C in the dark until fluorescence 
microscopy. 
Immunohistochemistry for CD31 after transplantation 
The rat brain sections were fixed in 4% 
paraformaldehyde in PBST, pH 7.4 for 10 min and 
washed three times in PBST for 5 min each. Then the 
slides were blocked for 30 min in Seablock solution 
(Pierce, Rockford, IL, USA) and washed three times in 
PBST for 5 min each. The primary anti-CD31 antibody 
(1:50; BD Biosciences, Heidelberg, Germany) for 
detecting endothelial cells/capillaries was applied 
overnight at 4 °C in a humidified chamber. The next 
day, the slides were washed 3 times for 5 min in PBST. 
For double staining, the second primary antibody was 
applied. Then the sections were incubated with the 
TRITC-conjugated secondary antibody (1:200, Jackson 
ImmunoResearch, West Grove, PA, USA) for 3 h at 
room temperature. After washing 3 times for 5 min 
each with PBST, nuclei were stained with 
4',6-diamidino-2-phenylindole (DAPI, 1:5,000, 
Molecular Probes, Eugene, OR, USA) for 5 min. Slides 
were embedded in fluoprotective mounting media [17] 
and stored at 4 °C in the dark until fluorescence 
microscopy.  
Image analysis 
Using the MCID Elite software, version 7.0 
(ImagingResearch, St. Cathrines, Ontario, Canada), 
and a digital camera (CoolSnap cf, Roper Scientific, 
Tucson, AZ, USA; DAGE 300, MTI, Michigan City, IN, 
USA) we took automated tiled field images on a 
fluorescent microscope (DM-LR, Leica Microsystems, 
Bensheim, Germany). To estimate the total number of 
stained cells, the optical disector method was applied 
according to [21]. This unbiased stereological method 
is based on systematically counting of labeled cells 
with optical dissectors in a uniform sample which 
constitutes a known fraction of the volume of the 
region to be analyzed. Unbiased stereological methods 
do not require any assumptions with regard to the 
shape of the objects. Thus all objects, e. g. cells, in a 
given tissue section are sampled with the equal 
probability regardless of their shape or position. 
The number of immunopositive cells in the brain 
sections was estimated using the optical disector 
technique. The disector frames had dimensions of 20 
µm x 20 µm. These frames were spaced in 20 µm 
distance. Disector frames were sampled randomly 
throughout the regions of interest. Targets were 
counted within or when touching the inclusion 
borders of the optical disector frame. Using the 
stereology study mode of the MCID Elite software, 
version 7.0 (ImagingResearch, St. Cathrines, Ontario, 
Canada), we estimated the number of cells in the 
region of interest. 
For cytometry and cell differentiation staining, 
images were recorded using semi-automated system 
equipped with a digital camera (PixelFly QE, PCO, 
Kehlheim, Germany) mounted on a fluorescent 
microscope (Zeiss Axiovert 200M, Zeiss, Göttingen, 
Germany). Standardized automatic acquisition was 
performed by AQuest software (TissueGnostics, 
Vienna, Austria) controlling filters, exposure, camera, 
and motor stage (Märzhäuser, Wetzlar, Germany). For 
image cytometry, all images were processed in the 
TissueQuest software (TissueGnostics, Vienna, 
Austria). Nuclei were detected by dissection 
algorithms in the DAPI channel. Then, 
immunopositive cells were detected by a non-annular 
signal grow algorithm around the nuclei. The signals 
for the respective primary antibody were plotted 
against the nuclear DAPI signals to create FACS-like 
scattergrams [16]. 
Statistical analysis 
Results were compared by one-factorial ANalysis 
Of VAriance (ANOVA) with Bonferroni's correction 
for multiple testing using the SPSS 9.01 statistical 
software package (SPSS, Chicago, IL, USA). A P-value 
< 0.05 was considered statistically significant. 
3.  Results and Discussion 
Viral transfection with VEGF increases the survival of 
neural stem cells after transplantation 
VEGF has been described as neuroprotective 
factor in vitro [3, 22] and in vivo [23]. In most studies, 
VEGF was added to the cell culture medium (e. g. in [3, 
24]) or its local concentration in the brain was 
increased by injection or transfection (e. g. in [18]) and 
increased the survival and differentiation of cells 
transplanted into the central nervous system. A major 
problem of these studies was the delivery of VEGF, 
since preincubation of the graft or intracerebral 
transfection increases the local cerebral VEGF 
concentration only temporarily. A combination of 
grafting cells into the brain and transfecting the cells 
with VEGF may be a suitable solution.  
A prerequisite of any transplantation study is to 
characterize the graft previous to the transplantation. 
Therefore, we characterized the cultured NPCs by 
immunostaining for multiple cellular markers (Fig. 1). 
Whereas the NPC markers Nestin and Doublecortin as 
well as the neuronal markers Tubulin-ßIII and 
neurofilament 70 kDa NF70 are expressed in the graft, 
only faint immunoreactivity is found for astrocytic 
(GFAP) and oligodendrocytic (O4) markers, and no 
immunoreactivity for endothelial cells/capillaries 
(CD31). Int. J. Biol. Sci. 2008, 4 
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Fig. 1. Immunohistochemical characterization of the cultured NPCs. We stained the cultured cells using a set of different antibodies 
directed against marker proteins for precursor cells (A, nestin; B, doublecortin DCX), neurons (C, tubulin ßIII, clone TuJ-1; D, 
neurofilament 70 kDa NF70), astrocytes (E, glial acidic fibrillary protein GFAP), oligodendrocytes (F, O4), and endothelial 
cells/capillaries (G, CD31). Additionally, the respective controls for the secondary fluorescent antibodies labeled with Cy3 (H) and 
Cy5 (I) are shown. The percentage in the upper right corner of each panel gives the percentage of cells positive for the respective 
marker. The NPCs are highly positive for progenitor cell markers and neuronal markers, but they do only show faint 
immunoreactivity for astrocytic and oligodendrocytic markers, and no immunoreactivity for CD31 as well as for the negative 
controls.  
 
 
 
In the present study, we investigated whether the 
transfection of NPCs with VEGF could increase the 
number of surviving neurons in the transplants. We 
introduced the VEGF-A165 g e n e  i n t o  N P C s  b y  
adenoviral vectors. NPCs showed a low basal 
expression of VEGF which was secreted into the cell 
culture medium at a concentration of about 12.1 ± 12.2 
pg/mL (N=12 biological replicates). After adenoviral 
transfection, the medium concentration of VEGF 
strongly increased to 243.1 ± 37.2 pg/mL (N=12 
biological replicates; P<0.05) (Fig. 2) as soon as 24 h 
after transfection and was stable for at least 6 weeks 
(data not shown). The transfection efficiency was 
measured by cell counting and revealed 20-30% of 
transfected cells. Thus the secreted concentration of 
VEGF per cell may be even higher. 
We then grafted VEGF-transfected and 
non-transfected NPCs into the intact, non-diseased rat 
brain and measured cellular survival 24 h, 4 d, and 11 
d after transplantation by cell counting in a 
stereological paradigm. Whereas we did not see 
differences in the survival rates of transfected versus 
non-transfected cells after 24 h or 4 d, VEGF labeling 
resulted in a doubling of the number of surviving cells 
11 d after the transplantation (N=4 animals in each 
group; P<0.05) (Fig. 3).  
In a previous study, the effects of the alternative 
splice form VEGF -A121 on the survival of transfected 
and grafted embryonic stem cells (day E14) were 
investigated in a rat model of brain ischemia [25]. The Int. J. Biol. Sci. 2008, 4 
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authors found that pretreatment with VEGF-A121 
increased the survival of the transplanted cells and 
ameliorated sensorimotor behavior of the diseased 
animals. In the non-diseased brain, a stimulus 
promoting the survival of neural stem and progenitor 
cells may be absent. The cells then become apoptotic, 
unless factors of the local microenvironment prevent 
cell death. Under physiological conditions, there is a 
low basal expression of VEGF in the brain, which is 
dramatically increased under pathophysiological 
stimuli such as hypoxia [26, 27]. In the present study, 
we show that the local concentration of VEGF was 
increased in the brain microenvironment after the 
transplantation of VEGF-transfected cells. In an 
autocrine mode of action [28], VEGF overexpression 
then resulted in an increased survival of the NPCs.  
 
Transplantation of VEGF-transfected NPCs increases 
the number of CD31-positive cells in the brain  
Besides its neuroprotective effects, VEGF is 
originally known for its role in angiogenesis [4, 29]. 
Therefore, we were interested to which extend the 
VEGF-transfected, transplanted cells may contribute to 
the increase in angiogenic cells. The Platelet 
Endothelial Cell Adhesion Molecule-1 protein 
(PECAM-1, CD31) is considered as marker protein for 
endothelial cells [30]. In the present study, we stained 
rat brain sections after transplantation of 
VEGF-transfected NPCs for the expression of 
PECAM-1. We found higher numbers of 
PECAM-1-positive cells after 24 h, 4 d, and 11 d in the 
brains with VEGF-transfected transplants as compared 
to grafts containing the empty vector (P < 0.05; N=4) 
(Fig. 4). Although the absolute number of 
PECAM-1-positive cells decreased over time, 
transfection with VEGF produced relatively more 
PECAM-1-positive cells. 
In general, transplanted cells seem to integrate or 
produce vessel-like structures in the brain. This is in 
accordance with other transplantation studies [31, 32], 
where increased survival of transplanted cells and 
endothelial differentiation have been described. 
Currently, it is unclear to which extend transplanted 
neural stem or progenitor cells attract the growth of 
blood vessels, or if they are able to differentiate into 
b l o o d  v e s s e l s  [ 3 3 ,  3 4 ] .  I n  t h e  t h e o r y  o f  t h e  
neurovascular niche, both hypotheses are supported in 
the literature, as well as in the present study.  
 
 
 
 
 
Fig. 2. VEGF expression in NPCs. (A) Immunostaining for VEGF (red). The antibody detects the VEGF-A165 isoform. Nuclei are 
counterstained with DAPI. (Scale bar, 25 µm). (B) VEGF expression in NPCs measured by ELISA. Whereas neural stem cells 
secrete about 20 pg/mL VEGF into the cell culture medium, adenoviral transfection with VEGF resulted in a more than 20-fold 
increase in the medium concentration.  
 Int. J. Biol. Sci. 2008, 4 
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Fig. 3. Survival of transplanted neural stem cells. One day and 4 
days after the transplantation, no differences can be seen 
between the VEGF-transfected and control (empty vector) 
NPCs. Only after 11 days, an increase of about 1.8-fold in cell 
numbers in the sections can be found (*, P < 0.05). VEGF 
rescues transplanted neural stem cells.  
 
 
 
 
Fig. 4. Expression of the endothelial cell marker PECAM-1 
(CD31). Higher numbers of CD31-positive cells can be seen for 
animals transplanted with VEGF-containing vectors compared 
to the transplantation of cells containing the empty control 
vectors for 24 h, 4 d, and 11 d after the transplantation (*, P < 
0.05). In accordance with the survival analysis, the number of 
CD31-positive cells decreases over time in both groups. 
 
4.  Conclusions 
Whereas the number of grafted adult neural 
progenitor cells decreases rapidly after transplantation 
into intact, non-diseased brain tissue, stimulation with 
VEGF-A165 rescues transplanted NPCs from cell death. 
Thus grafting of VEGF-transfected cells may bring 
additional value to the survival of transplants as 
compared to non-transfected cells. Moreover, 
transplantation of VEGF-transfected cells increases the 
number of PECAM-1-positive cells in the brain, 
indicating increased angiogenesis in the target regions. 
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